Gensing Dragons


    Baicalin and Baicalein: The Health Benefits of This Flavanoid

    Share
    avatar
    Admin
    Admin

    Posts : 4
    Join date : 2016-10-04

    Baicalin and Baicalein: The Health Benefits of This Flavanoid

    Post by Admin on Tue Oct 11, 2016 11:16 am

    Introduction


    Baicalein is a flavone, a type of polyphenolic flavonoid, that is extracted from the roots of Scutellaria baicalensis and Scutellaria lateriflora that have a wide variety of health benefits.

    Baicalin is a flavone glycoside, the glucuronide of baicalein, which is obtained through the binding of glucuronic acid to baicalein. It is primarily used in Asian countries as an herbal supplement.



    The Baicalin That I Recommend

    Baicalin by lift mode (AMZN)

    Health Benefits of Baicalin and Baicalein

    1 ) Baicalein and Baicalin Lowers Anxiety

    Baicalein and baicalin inhibit the action potential of the neurons that raise anxiety (https://www.thieme-connect.com/DOI/DOI?10.1055/s-0029-1243121).

    In mice, baicalin produces anxiety-lowering effects without causing drowsiness or muscle relaxation (http://www.sciencedirect.com/science/article/pii/S0028390808003250).

    2 ) Baicalein and Baicalin are Neuroprotective



    Baicalin improved cognitive dysfunction via its anti-neuroinflammatory activity, and may be a potential candidate for the treatment of Alzheimer’s Disease (AD) (https://www.ncbi.nlm.nih.gov/pubmed/25108596).

    It improved Amyloid beta-induced learning and memory deficit, hippocampus injury and neuron apoptosis (https://www.ncbi.nlm.nih.gov/pubmed/25596671).

    Baicalin improves learning and memory impairment induced by brain injury in mammals (https://www.ncbi.nlm.nih.gov/pubmed/27016057).

    Treatment with this flavonoid, post-stroke, promotes neuron development in damaged sections of the brain, including the new formation of cells in the hippocampus (https://www.ncbi.nlm.nih.gov/pubmed/23302221).

    3 ) Baicalein and Baicalin Fight Cancer



    Short-term treatment (48 hours) with baicalein inhibits the proliferation of human ovarian cancer cells.  An increase in cell death was observed when combined with Taxol (a chemotherapy drug) (https://www.ncbi.nlm.nih.gov/pubmed/27414207).

    Baicalein suppressed proliferation, migration, and invasion of breast cancer cells in a time and dose-dependent manner. It had the potential to suppress breast cancer metastasis (https://www.ncbi.nlm.nih.gov/pubmed/27143851).

    Baicalein, when ingested, is metabolized and inhibits the proliferation of human colorectal cancer cells (https://www.ncbi.nlm.nih.gov/pubmed/26398706).

    It destroys the S cycle of colorectal cancer cells, which promotes cell death and prevents further replication (https://www.ncbi.nlm.nih.gov/pubmed/24026776).

    Baicalin ingested at a dose of 100 mg/kg for 28 days decreases tumor growth and replication in mice with colon cancer cells (https://www.ncbi.nlm.nih.gov/pubmed/23157964).

    When taken orally for 7 days it increases the activity of T helper cells and T regulatory cells to fight chemically-induced colon cancer (https://www.ncbi.nlm.nih.gov/pubmed/25269538).

    Baicalin applied as a topical cream protects the skin with antioxidant effects. It also reduces UV-related apoptosis (cell death) (https://www.ncbi.nlm.nih.gov/pubmed/24292572, https://www.ncbi.nlm.nih.gov/pubmed/26783703).

    4 ) Baicalin Protects the Liver



    Baicalin administered in rats decreased the production of disease promoting proteins in the liver, reducing the effects of NAFLD (https://www.ncbi.nlm.nih.gov/pubmed/26889237).

    It decreases cholesterol, alanine transaminase, low-density lipoproteins, and TNF levels.

    Rats with alcohol-induced liver damage treated with this flavonoid before consuming alcohol had protective effects on the liver. It also decreased liver cell apoptosis (https://www.ncbi.nlm.nih.gov/pubmed/26936686).

    5 ) Baicalin Improves Lung Function



    Pure baicalin is successful at improving lung function in rats which suffer from allergic diseases (https://www.ncbi.nlm.nih.gov/pubmed/24447164).

    When administered to rats suffering from asthma as a pretreatment, showed a healthy remodeling of the airway (https://www.ncbi.nlm.nih.gov/pubmed/26884970).

    Baicalein reduces inflammation in silica-induced lung inflammation by inhibiting Th17 cells in the lungs (https://www.ncbi.nlm.nih.gov/pubmed/26605988).

    6) Baicalein and Baicalin Help Your Eyes



    Daily intake of baicalin or baicalein helps prevent eye diseases such as cataracts or age-related macular degeneration in animals (https://www.ncbi.nlm.nih.gov/pubmed/25280175).

    Oral intake reduces stress on the eyes and muscles, decreasing the chance of contracting an eye disease (https://www.ncbi.nlm.nih.gov/pubmed/22928823).

    7 ) Baicalin Improves Fertility




    Baicalin significantly enhances endometrial reproduction (https://www.ncbi.nlm.nih.gov/pubmed/25896022).

    In mice embryos, it increases development and quality of blastocysts (https://www.ncbi.nlm.nih.gov/pubmed/27478062).

    Buying & Dosage

    Baicalein and baicalin supplements can be taken by healthy individuals. The healthy dose should be 200-800 mg in multiple day doses, once in the morning and once again at night, without any side effects (https://www.ncbi.nlm.nih.gov/pubmed/27352310).

    Baicalin by lift mode (AMZN)
    Technical

    Baicalein is able to inhibit the Akt/Beta-catenin signaling pathway which prevents the further development of human ovarian cancer cells (https://www.ncbi.nlm.nih.gov/pubmed/27414207).
    It also inhibits MMP-2, MMP-9, uPA, and uPAR expressions, which prevent tumor growth and metastasis (https://www.ncbi.nlm.nih.gov/pubmed/23387975).
    Baicalein inhibits SATB1 protein synthesis which inhibits tumor formation in lab experiments (https://www.ncbi.nlm.nih.gov/pubmed/27143851).
    In combination with baicalein, baicalin inhibits the transcription proteins which lead to the transformation of epithelial cells into cancerous stem cells (epithelial-mesenchymal transition) (https://www.ncbi.nlm.nih.gov/pubmed/25686495).
    Glucose-related protein 78 levels were reversed with treatment of baicalin which improved overall liver function (https://www.ncbi.nlm.nih.gov/pubmed/26936686).

    8 ) Baicalin Is Good For Sleep



    In an animal study, scientists were able to demonstrate that baicalin can help to regulate proper sleeping cycles. Baicalin seems to regulate the natural rhythms of our sleep. It allows the ‘light period’ of sleep to function normally, and allows deeper REM sleep in the ‘dark period’.

    ICV administration of baicalin decreased slow wave sleep (SWS) during the first 2h of the light period. Rapid eye movement sleep (REMS) was not altered. The blockade of IL-1β-induced SWS enhancement by baicalin suggests that the antagonism of IL-1 receptors is involved in baicalin-induced SWS decrement during the light period. However, IL-1β concentrations during the light period were not altered after baicalin administration. In contrast, baicalin increased both SWS and REMS during hours 8-10 of the dark (active) period when baicalin was administered at the beginning of the dark period, and its effects were blocked by the GABA(A) receptor antagonist bicuculline.

    Baicalin exhibits biphasic effects on sleep-wake regulation; the decrease of SWS during the light period and increases of SWS and REMS during the dark period. Inhibition of IL-1 action and enhancement of GABA(A) receptor activity may mediate baicalin's effects during the light and dark period, respectively.

    https://www.ncbi.nlm.nih.gov/pubmed/21419210

    9 ) Baicalin Is A Helpful Pain-Reliever



    The study found that baicalin treatment was just as strong at reducing pain as a common pain-relief tablet in carrageenan-invoked rats (carrageenan is known to cause intestinal and inflammatory pain).

    Results showed that baicalin possesses an analgesic effect in carrageenan-evoked thermal hyperalgesia. The possible mechanisms of action of baicalin may be associated with the inhibition of proinflammatory mediator overproduction, including cytokines, nitric oxide, and prostaglandin E(2), as well as neutrophil infiltration. This implies that baicalin may be a potential therapeutic analgesic for inflammatory pain.

    https://www.ncbi.nlm.nih.gov/pubmed/14633550

    10 ) Baicalin Helps To Reduce Stress And Promote Relaxation



    People also use baicalin for reducing anxiety. Baicalin is actually a great anxiolytic (anxiety-inhibitor). This is because baicalin acts as a GABA-A substrate. Baicalin, a naturally occurring flavonoid, was previously reported to induce anxiolytic-like effect devoid of sedation and myorelaxation in mice, acting through type A gamma-aminobutyric acid (GABA(A)) receptor benzodiazepine (BZ) site. The present study further expanded the behavioral pharmacology profile of baicalin and subtype selectivity was explored as a possible mechanism underlying its in vivo effects on mice. Its subtype selectivity suggested that baicalin exerted its in vivo anxiolytic-like effect mainly through the alpha2- and alpha3-containing subtypes. Therefore, the present study revealed an underlying mechanism for the selective anxiolytic profile of baicalin, suggesting alpha2- and alpha3-containing subtypes were important drug targets for flavonoid-based anxiolytics.

    https://www.ncbi.nlm.nih.gov/pubmed/18723037

    GABA receptors are responsible for reducing the sensations from your central nervous system. Scientists agree that the sensation of pain is mediated by GABA-A receptors. By binding to these receptors, baicalin helps to reduce sensations of pain.

    http://www.pnas.org/content/102/3/915


    The great thing about this is that you can use baicalin for anxiety without affecting your cognitive abilities or making you feel drowsy.

    11 ) Baicalin Helps Prevent Harmful UV Rays



    You can use baicalin for protecting your skin from ‘reactive-oxygen species’. Ok, what are those? Reactive-oxygen species form when our skin is exposed to UV sunlight. They are a major cause of skin damage from sunlight, and baicalin helps to protect from these. In the current study, we examined whether baicalin could also effectively protect human keratinocytes from damaging short-wave UVC irradiation. Baicalin-scavenged reactive oxygen species increased within 2 h after UVC radiation. Baicalin also abrogated UVC-induced apoptosis. In addition, we identified the major products after UVC radiation with T4 UV endonuclease, finding that baicalin prevented cyclobutane pyrimidine dimer formation induced by UVC. Furthermore, baicalin also prevented formation of oxidative adducts induced by UVC.

    https://www.ncbi.nlm.nih.gov/pubmed/24292572


    Furthermore, scientists have proven that baicalin is great at protecting your fibroblasts, which are a key part of the outer layers of your skin. Interestingly, the use of baicalin after UVA radiation significantly reduced the level of intracellular O(2)(-), NO, and ROS, stabilized the mitochondrial membrane potential, and attenuated production of MDA and 8-oxo-dG. These efficiently enhanced the antioxidative defense system and protected the HSFs from subsequent oxidative stress damage and apoptosis. In other words, baicalin decreased the excessive generation of intracellular ROS and NO, and elevated the cellular antioxidative defense, which eventually mitigate the UVA-induced apoptosis. Based on our results, baicalin may have applications in the treatment of skin photodamage caused by UVA irradiation.

    https://www.ncbi.nlm.nih.gov/pubmed/22946442



    *New Studies done by the Ulsan National Institute of Science and Technology*
    Cancer Breakthrough at UNIST, Using Plant-derived Baicalein

    http://sls.unist.ac.kr/en/board/view.asp?part=N4&seq=1186&page=1&pstr=&cate=5

    The UNIST-PNUYH Joint Symposium was held at PNUYH on the 30th of August, 2016.
    UNIST and PNUYH to hold a joint symposium on "Coping with Incurable Disease".

    Aug 31

    "UNIST has announced a unique collaboration with Pusan National University Yangsan Hospital (PNUYH) to accelerate the development of new drugs to treat incurable diseases, ranging from diabetes to cancer. The collaboration will comprise UNIST’s Center for Cell to Cell Communication in Cancer (C5) and PNUYH’s Research Institute for Convergence of Biomedical Science and Technology and will provide new impetus for South Korea to lead the world in biomedical research. Both organizations have outlined the important future research directions for the treatment of many as-yet-incurable diseases at the UNIST-PNUYH Joint Symposium, held at PNUYH on the 30th of August, 2016. The theme for the symposium was “Convergence Study of Bio-Medical to Conquer Incurable Diseases”. This symposium aimed to advance knowledge and expertise in new drug development, through multi-disciplinary collaborations of the cancer research community to further improve the care and outcomes of the patients with incurable diseases. Director Pann-Ghill Suh of Center for Cell to Cell Communication in Cancer (C5) at the UNIST-PNUYH Symposium on Aug. 30th, 2016. At the event, Director Pann-Ghill Suh of C5 and Prof. KangYeol Choi of Yonsei University presented a new phenomenon of cancer metastasis and released the new targeted cancer theraphy that overcomes the problems with currently existing treatments. Director Suh also presented a new direction for the development of colorectal cancer by discovering the phenomenon, in which broken cellular signals in malfunctioning cancer cells is the leading cause of the colorectal cancer. Also, Prof. SuJin Moon and Prof. SangSoo Lee of PNUYH, and Prof. Hyug Moo Kwon of UNIST talked about the causes, diagnosis, and potential treatment of incurable diseases, as well as translational research method for the development of new treatment technologies. Translational research applies findings from basic science to enhance human health and well-being. In a medical research context, it aims to “translate” findings in fundamental research into medical practice and meaningful health outcomes. Director Suh states, “Clinical research in UNIST is set to be strengthened by a new collaboration launched, today.” He continues, “With this MOU, we hope to create and promote high-value added, innovative biomedical industry in the southeast region.”

    Cancer Breakthrough at UNIST, Using Plant-derived Baicalein

    http://sls.unist.ac.kr/en/board/view.asp?part=N4&seq=1201&page=1&pstr=&cate=5

    "A new study, led by Prof. Kyungjae Myung (School of Life Sciences), Director of the IBS Center of Genome Integrity has revealed breakthrough inhibition of colon tumors in mice with mismatch repair deficiency. The findings, published in the June 6th issue of the American Association for Cancer Research, suggest that this is a significant breakthrough for the future treatment of colon cancer patients, specifically for those with DNA mismatch repair (MMR) deficient tumors. Baicalein inhibits the growth of AOM-DSS-induced colon tumors in mice and the model for baicalein activity in MutSα-proficient and MutSα-deficient cells. Baicalein has been reported to have some anti-inflammatory(33) and antiproliferative(16) effects. In the study, the research team discovered that baicalein is not only a small molecule that selectively kills MutSα-deficient cancer cells, but also offers several advantages over other MSH2-mutant sensitizing drugs, such as methotrexate and psoralen. In the study, two distinct mice models were used to test their hypothesis. They were induced with colon tumors and exposed to a constant dose of baicalein over a two week period. Apoptotic cell death increased two fold by baicalein in MutSα-deficient tumors. The results show that Baicalein continued to significantly shrink the MutSα-deficient tumors. Prof. Myung notes that “This research finding has great potential to target cancer therapy for patients who are diagnosed with mismatch repair deficient tumors. These particular types of tumors cover 10% of colon cancers.” This work has been supported by the Creative Research Initiative, BK21 Plus, and Mid-Career Researcher programs through the National Research Foundation of Korea. Journal Reference Yongliang Zhang, Jennifer T Fox, Young-Un Park, Gene Elliott, Ganesha Rai, Mengli Cai, Srilatha Sakamuru, Ruili Huang, Menghang Xia, Kyeryoung Lee, Min Ho Jeon, Bijoy p Mathew, Hee Dong Park, Winfried Edelmann, Chan Young Park, Sung You Hong, David Maloney, and Kyungjae Myung. “A novel chemotherapeutic agent to treat tumors with DNA mismatch repair deficiencies,” Cancer Research, (2016)."


    _________________

      Current date/time is Thu Nov 23, 2017 6:17 pm